

Clinical Policy: Bendamustine (Belrapzo, Bendeka, Treanda, Vivimusta) Reference Number: LA.PHAR.307

Effective Date: 10.02.22 Last Review Date: 01.15.2505.20.24 Line of Business: Medicaid

I

Coding Implications Revision Log


See <u>Important Reminder</u> at the end of this policy for important regulatory and legal information.

Please note: This policy is for medical benefit	Formatted: Font: Bold	
A	Formatted: Font: Bold	
Description Bendamustine hydrochloride (Belrapzo [®] , Bendeka [®] , Treanda [®] , Vivimusta ^{x_{M}}) is an alkylating drug.		
	Formatted: Font color: Black	
 FDA Approved Indication(s) Belrapzo, Bendeka, Treanda, and Vivimusta are indicated for the treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. 		
Policy/Criteria Provider must submit documentation (such as office chart notes and lab results or other clinical information) supporting that member has met all approval criteria.		
It is the policy of Louisiana HealthCare Connections [®] that Belrapzo, Bendeka, Treanda, and Vivimusta, and Bendamustine are medically necessary when the following criteria are met:	Formatted: Tab stops: 2.31", Left	
 Initial Approval Criteria A. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (must meet all): Diagnosis of chronic lymphocytic leukemia (CLL) (i.e., or small lymphocytic lymphoma [(SLL]);); Prescribed by or in consultation with an oncologist or hematologist; Age ≥ 18 years; Prescribed in combination with rituximab or Gazyva[®]; Request meets one of the following (a or b):* Dose does not exceed 100 mg/m² on Days 1 and 2 of a 28-day cycle, up to 6 cycles; Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). *Prescribed regimen must be FDA-approved or recommended by NCCN Approval duration: 6 months 		
	Formatted: Indent: Left: 0.5"	
 B. Non-Hodgkin B-Cell Lymphomas (must meet all): 1. One of the following diagnoses (a-through k-h): 		


Page 1 of 11



a. Indolent B-cell non-Hodgkin lymphoma that has progressed during or within six	
months of treatment with rituximab or a rituximab-containing regimen;	
b. FollicularClassic follicular lymphoma;	
c. Marginal zone lymphoma (MZL) (i, ii, or iii):	
i. Splenic MZL;	
ii. Nodal MZL:	
iii. Extranodal mucosa-associated lymphoid tissues (MALT) (1 or 2):	
e.1)Gastric MALT lymphoma;	Formatted
d.2) Nongastric MALT lymphoma;	Formatted: Formatted: Bullets and Numbering
e. Nodal marginal zone lymphoma;	Formatted: Bullets and Numbering
e Notal marginal zone lymphoma; f Splenic marginal zone lymphoma;	
	Formettade Dullate and Numbering
g.d. Mantle cell lymphoma;	Formatted: Bullets and Numbering
h.e. Diffuse large B-cell lymphoma (DLBCL) (with no intention to proceed to	
transplant, as subsequent therapy);*:*	Formatted: Font: Not Italic
i.f. HIV-related B-cell lymphoma (, as subsequent therapy);*;*	Formatted: Font: Not Italic
j.g. Monomorphic post-transplant lymphoproliferative disorder (PTLD) (B-cell type)	
(), as subsequent therapy);*:*	Formatted: Font: Not Italic
k.h.High-grade B-cell lymphomas: not otherwise specified or with translocations of	
MYC and BCL2 and/or BCL6 (double/triple hit lymphoma) (with no intention to	
proceed to transplant, as subsequent therapy);*:*	Formatted: Font: Not Italic
*See Appendix B - prior authorization may be required for prior therapies	
2. Prescribed by or in consultation with an oncologist or hematologist;	
. Age ≥ 18 years;	
. For nodal/splenic marginal zoneclassic follicular lymphoma-or gastric/nongastric	
MALT lymphoma, MZL: prescribed in combination with rituximab or Gazyva;*	
5. For mantle cell lymphoma; prescribed in combination with rituximab;	
5. For indolent B-cell non-Hodgkin lymphoma, DLBCL, HIV-related B-cell lymphoma,	
PTLD, high-grade B-cell lymphomas: prescribed in combination with Polivy [®] with or	
without rituximab;	
-7. Request meets one of the following (a or b):*	Formatted: Bullets and Numbering
a. Dose does not exceed 120 mg/m ² on Days 1 and 2 of a 21-day cycle, up to 8	
cycles;	
b. Dose is supported by practice guidelines or peer-reviewed literature for the	
relevant off-label use (<i>prescriber must submit supporting evidence</i>).	
*Prescribed regimen must be FDA-approved or recommended by NCCN	
Approval duration: 6 months	
II	
NCCN Recommended Uses (off-label) (must meet all):	
. Diagnosis of one of the following (a , b, c, d, e, f, or <u>g</u>.h):	
a. Classic or nodular lymphocyte-predominant-Hodgkin lymphoma (HL) (that is	
relapsed or refractory, as subsequent therapy $\frac{1}{2}$,*	Formatted: Font: Not Italic
b. Pediatric HL (that is relapsed or refractory, as re-induction or subsequent	Formatted: Font: Not Italic
therapy);*	romatica. Font. Not flanc
uiciup <i>y</i>), <u>.</u>	



Page 3 of 11



Page 4 of 11



Appendix A: Abbreviation/Acronym Key AITL: angioimmunoblastic T-cell lymphoma ALCL: anaplastic large cell lymphoma ATLL: adult T-cell leukemia/lymphoma CLL: chronic lymphocytic leukemia CNS: central nervous system DLBCL: diffuse large B-cell lymphoma EATL: enteropathy-associated T-cell lymphoma FDA: Food and Drug Administration HIV: human immunodeficiency virus HL: Hodgkin lymphoma HSTCL: hepatosplenic gamma-delta Tcell lymphoma MALT: mucosa-associated lymphoid <u>tissue</u> MEITL: monomorphic epitheliotropic

intestinal T-cell lymphoma

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum	
		Dose	
Examples of primary therapies	(NCCN)		
DLBCLB-cell NHL (e.g., DLBCL, HIV-related B-cell l	ymphoma, P'	<u>TCL)</u>	
RCHOP	Varies	Varies	
<u>{</u> Rituxan [®] <u>{(</u> rituximab],) + (cyclophosphamide,			
doxorubicin, vincristine, prednisone)			
EPOCH	Varies	Varies	
_(etoposide, prednisone, vincristine, cyclophosphamide,			
doxorubicin) + Rituxan [®] (rituximab)			
HIV-related B-cell lymphoma			
RCDOPEPOCH (etoposide, prednisone, vincristine,	Varies	Varies	Formatted: Font color: Auto
cyclophosphamide, doxorubicin) + Rituxan [®] (rituximab)			
+ (cyclophosphamide, liposomal doxorubicin,			
vincristine, prednisone)			



MF: mycosis fungoides

MM: multiple myeloma

Network

disorder

MCL: marginal zone lymphoma

NHL: non-Hodgkin lymphoma PTCL: peripheral T-cell lymphoma

PTLD-NOS: post-transplant

otherwise specified

SS: Sezary syndrome <u>TFH: follicular T-cell</u>

lymphoproliferative disorder not

SLCA: systemic light chain amyloidosis SLL: small lymphocytic lymphoma

NCCN: National Comprehensive Cancer

PTLD: post-transplant lymphoproliferative



Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose		
<u>CHOPRCEOP Rituxan[®] (rituximab) +</u>	Varies	Varies		Formatted: Font color: Auto
(cyclophosphamide, doxorubicinetoposide, vincristine,				
prednisone) + Rituxan [®] (rituximab)				
PTCL RGCVP Rituxan [®] (rituximab) + (gemcitabine,	Varies	Varies	•	Inserted Cells
cyclophosphamide, vincristine, prednisone)			$\overline{}$	Inserted Cells
<u>RCEPP Rituxan[®] (rituximab) + (cyclophosphamide,</u>	<u>Varies</u>	<u>Varies</u>		Formatted Table
etoposide, prednisone, procarbazine)				Formatted: Font: Not Bold
CHOP (Pola-R-CHP (Polivy [polatuzumab vedotin-piiq],	Varies	Varies		Formatted: Font color: Auto
Rituxan [rituximab], cyclophosphamide, doxorubicin,				
vincristine, prednisone)				
HL				
ABVD (doxorubicin, bleomycin, vinblastine,	Varies	Varies		
<u>dacarbazine) + Rituxan (rituximab)</u>				
EPOCH (etoposide, prednisone, vincristine, RCHOP	Varies	Varies		Formatted: Font color: Auto
<u>Rituxan (rituximab) + (</u> cyclophosphamide, doxorubicin,				
vincristine, prednisone)				
CVbp (cyclophosphamide, vinblastine, prednisolone) +	Varies	Varies		
<u>Rituxan (rituximab)</u>				
<u>Rituxan (rituximab)</u>	Varies	Varies		
MM				
Bortezomib/lenalidomide/dexamethasone	Varies	Varies		
Carfilzomib/lenalidomide/dexamethasone	Varies	Varies		
Daratumumab/lenalidomide/dexamethasone	Varies	Varies		
ATLLT-cell Lymphomas (e.g., HSTCL, ATLL, ALCL,	PTCL)			
ICE (ifosfamide, carboplatin, etoposide)	Varies	Varies		
DHAP (dexamethasone, and cisplatin, cytarabine) +	Varies	Varies		
platinum (carboplatin, cisplatin, or oxaliplatin)				
EPOCH <mark>CHOP (</mark>	Varies	Varies		Formatted: Font color: Auto
(etoposide, prednisone, vincristine, cyclophosphamide,		•		
doxorubicin, vincristine, prednisone) + Rituxan				
(rituximab)				
HyperCVAD (cyclophosphamide, vincristine,	Varies	Varies		
doxorubicin, dexamethasone) alternating with high-dose				
methotrexate and cytarabine				
HSTCL				
DHAP (dexamethasone, cisplatin, cytarabine)	Varies	Varies		
ICE (ifosfamide, carboplatin, etoposide)	Varies	Varies		
MM				
Bortezomib/liposomal doxorubicin/dexamethasone	Varies	Varies		
Carfilzomib/lenalidomide/dexamethasone	Varies	Varies		



Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose	
Daratumumab/bortezomib /dexamethasone	Varies	Varies	
Monomorphic PTLD (B-cell type)			
RCHOP	Varies	Varies	Formatted: Font color: Auto
(Rituxan [®] [rituximab], CHOEP (cyclophosphamide,			
doxorubicin, vincristine, etoposide, prednisone)			
RCEPP (Rituxan [®] [rituximab], CHOP	Varies	Varies	
(cyclophosphamide, etoposidedoxorubicin, vincristine,			
prednisone , procarbazine)			
SLCA			
Daratumumab and hyaluronidase-	Varies	Varies	
fihj/bortezomib/cyclophosphamide/dexamethasonePolivy			
(brentuximab vedotin) \pm CHP (cyclophosmaide,			
doxorubicin, prednisone)			

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

• Contraindication(s):

- Belrapzo, Bendeka: patients with a history of a hypersensitivity reaction to <u>bendamustineBendamustine</u>, polyethylene glycol 400, propylene glycol, or monothioglycerol
- Treanda: patients with a history of a hypersensitivity reaction to bendamustineBendamustine
- Vivimusta: patients with a history of a hypersensitivity reaction to bendamustineBendamustine, polyethylene glycol 400, dehydrated alcohol, or monothioglycerol
- Boxed warning(s): none reported

V. Dosage and Administration

Dosing Regimen	Maximum Dose
Bendeka: 100 mg/m ² IV over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles	See regimen
Belrapzo, Treanda: 100 mg/m ² IV over 30 minutes on days 1 and 2 of a 28-day cycle, up to 6 cycles	
Vivimusta: 100 mg/m^2 IV over 20 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles	
Bendeka: 120 mg/m ² IV over 10 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles	See regimen
	Dosing RegimenBendeka: 100 mg/m² IV over 10 minutes on Days 1and 2 of a 28-day cycle, up to 6 cyclesBelrapzo, Treanda: 100 mg/m² IV over 30 minutes ondays 1 and 2 of a 28-day cycle, up to 6 cyclesVivimusta: 100 mg/m² IV over 20 minutes on Days 1and 2 of a 28-day cycle, up to 6 cyclesBendeka: 120 mg/m² IV over 10 minutes on Days 1



Indication	Dosing Regimen	Maximum Dose
	Belrapzo, Treanda: 120 mg/m ² IV over 60 minutes on days 1 and 2 of a 21-day cycle, up to 8 cycles	
	Vivimusta: 120 mg/m ² IV over 20 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles	

*Non-Hodgkin lymphomas

VI. Product Availability

1 Founder 11 values inty						
Drug Name	Availability					
Bendamustine (Belrapzo,	Solution (multiple-dose vial): 100 mg/4 mL					
Bendeka, Vivimusta)						
Bendamustine (Treanda)	Solution (single dose vial): 45 mg/0.5 mL; 180 mg/2 mL					
	Lyophilized powder (single-dose vial): 25 mg in a 20 mL					
	vial; 100 mg in a 20 mL vial					

VII. References

- Belrapzo Prescribing Information. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc; June 2022January 2024. Available at: www.belrapzo.com. Accessed August <u>10, 20236, 2024</u>.
- Bendeka Prescribing Information. North Wales, PAParsippany, NJ: Teva Pharmaceuticals USA, Inc.; October 2021..; January 2024. Available at: httphttps://www.bendeka.com/_accessdata.fda.gov/drugsatfda_docs/label/2024/208194s026lb l.pdf. Accessed August 10, 20236, 2024.
- Treanda Prescribing Information. <u>North Wales, PAParsippany, NJ</u>: Teva Pharmaceuticals USA, Inc.; October 2022. Available at: https://www.treandahep.com/globalassets/treandahcp/pdf/treanda_final_piaccessdata.fda.gov/drugsatfda_docs/label/2022/022249s026lbl.pdf. Accessed August 10, 20236, 2024.
- Vivimusta Prescribing Information. Princeton, NJ: Slayback Pharma; December 2022.February 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212209s000lbl2024/212209s005 lbl.pdf. Accessed August 10, 20236, 2024.
- 5. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. August 10, 20236, 2024.
- National Comprehensive Cancer Network. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.20232024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed August 10, 20236. 2024.
- National Comprehensive Cancer Network. B-cell Lymphomas Version 5.20232.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. August 10, 20236, 2024.
- National Comprehensive Cancer Network. Hodgkin Lymphoma Version 2.20233.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed August 10, 20236, 2024.

Page 8 of 11



- National Comprehensive Cancer Network. Multiple Myeloma Version <u>3.20234.2024</u>. Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed August <u>10, 20236, 2024</u>.
- National Comprehensive Cancer Network. T-cell Lymphomas Version <u>1.20234.2024</u>. Available at: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed August <u>106</u>, 2023.
- National Comprehensive Cancer Network. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Version <u>1.20232.2024</u>. Available at: https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf. Accessed August <u>10, 20236, 2024</u>.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-todate sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS	Description
Codes	
J9033	Injection, bendamustine HCl (Treanda), hydrochloride, 1 mg
J9034	Injection, bendamustine HCl (Bendeka), 1 mg
J9036	Injection, bendamustine HCl, (Belrapzohydrochloride, (belrapzo/bendamustine), 1
	mg
C9399	Unclassified drugs or biologicals (Vivimusta)
J9999	Not otherwise classified, antineoplastic drugs (Vivimusta)
J9056	Injection, bendamustine hydrochloride (<u>V</u> vivimusta), 1 mg
J9058	Injection, bendamustine hydrochloride (apotex), 1 mg
J9059	Injection, bendamustine hydrochloride (baxter), 1 mg

Reviews, Revisions, and Approvals	Date	LDH	 Formatted Table
		Approv al Date	
Converted corporate to local policy	07.22	10.02.22	Formatted: Font color: Text 1
Added new dosage form Vivimusta. Added SLCA and hematopoietic	06.02.23	10.05.23	Formatted: Indent: Left: 0", Hanging: 0.63"
cell transplantation under NCCN recommended use given category 2A recommendation.			Formatted: Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers
Removed primary cutaneous lymphomas as use is no longer supported			Formatted Table
by NCCN primary cutaneous lymphoma guideline.			
References reviewed and updated.			
Template changes applied to other diagnoses/indications			
Annual review: removed combination use with Arzerra for CLL from initial criteria as use is no longer supported by NCCN CLL/SLL	05.20.24	07.29.24	Formatted: Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers
guideline; renamed AIDS-related B-cell lymphoma to HIV-related per			Formatted: Centered



Reviews, Revisions, and Approvals	Date	LDH Approv al Date	Formatted Table
NCCN naming changes; references reviewed and updated. Added HCPCS codes [J9056, J9058, J9059].			
Annual review; clarified that policy applies to generic Bendamustine; for all indications, for NHL per NCCN, clarified follicular lymphoma is classic, updated formatting for MZL to clarify types; specified DLBL is with no intention to precede to transplant, revised high-grade B-cell lymphoma criteria to lymphoma with no intention to proceed to transplant, added requirements for combination use for classic follicular lymphoma, MZL, indolent NHL, DLBCL, HIV-related B-cell lymphoma, PTLD, and high-grade B-cell lymphoma per NCCN; for off- label NCCN uses per NCCN, added relapsed or refractory requirements to HL, MM, and SLCA, added as subsequent therapy requirement to MM and PTCL, added initial therapy requirement to PTCL; added off- label indications of MF/SS, EATL, and ALCL, clarified PTCL subtypes, clarified Waldenstrom's macroglobulinemia includes Bing- Neel syndrome, added requirements for combination use for T-cell lymphomas, MF/SS, and Waldenstrom's macroglobulinemia; updated Appendix B per NCCN; removed Bendamustine 45mg and 180mg vials per product discontinuation; HCPCS codes removed [J9058, J9059] and revised description [J9033]; references reviewed and updated.	01.15.25		Formatted Table

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

Page 10 of 11



This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©20252024 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.

Page 11 of 11